|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- June 29, 2006
CopyrightCOPYRIGHT 2006 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Adventrx Pharmaceuticals Inc., of San Diego, began a pivotal Phase III trial of its chemotherapy-enhancing drug, CoFactor, in metastatic colorectal cancer. It will randomize 1,200 patients to two arms containing either CoFactor or leucovorin, each in combination with 5-FU and Avastin (bevacizumab, from Genentech Inc.). The primary endpoint is progression-free survival, and secondary endpoints include response rates, overall survival and the incidence and severity of adverse events. The protocol and planned analysis were accepted by the FDA under a special protocol assessment reported last month. On Wednesday, shares in the company (AMEX:ANX) gained 70 cents, or 21.9 ...
Related newspaper, magazine, and journal articles:
|
|
Article: Eisai Inc. Opens New Facility in Research Triangle ...
PR Newswire;
November 19, 2003 ;
700+ words
...RESEARCH TRIANGLE PARK, N.C., Nov. 19 /PRNewswire ... manufacturing and R&D site in Research Triangle Park, North Carolina. The new 80 ... treatments that are produced at their Research Triangle Park facility." Other special guests ...
|
|